In this Issue:
Physical fitness and long-term type 2 diabetes risk
PCSK9 inhibition beneficial in type 2 diabetes
SGLT2 inhibitors may protect against CV outcomes and death
No link between egg consumption and type 2 diabetes risk
Worse complications with younger age of type 2 diabetes onset
Liraglutide: CV benefit in type 2 diabetes
Empaglifozin slows progression of renal disease
ACCORD: Long-term follow-up data on intensive glycaemic control
The DCCT/EDIC study 30-year follow-up
Premature mortality with type 1 diabetes
Please login below to download this issue (PDF)